Together with a recent report (Liu et al, 2018), these results demonstrate that partial suppression of STAG1 triggers strong and selective anti-proliferative effects in STAG2-mutant cancer models in vitro and in vivo and further reinforces the hypothesis that STAG1 should be pursued as a promising concept for therapy development. Here, STAG1 is linked to cancer.